Benzinga · Feb 3, 2026
PY
NASDAQ · PYXS
Pyxis Oncology, Inc. Common Stock
Healthcare · Biotechnology
$3.27
Down-$0.06 (-1.83%)
Updated Sep 11, 2026, 8:51 PM
SID Score
6.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 274.21M
- P/E ratio
- -2.84
- Dividend yield
- 0.00%
- 52-week range
- $1.03 – $5.55
- Volume
- 742.14K
- Avg. volume
- 793.75K
Price performance
PYXS price history
1M range · 20 trading sessions · Daily adjusted prices
PYXS closed at $3.27 after 20 trading sessions, up 8.64% for the selected period.
- Last close
- $3.27
- Period change
- +8.64%
- Period low
- $2.96
- Period high
- $3.89
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $3.42 | $3.4367 | $3.18 | $3.27 | 742.14K |
| Sep 9, 2026 | $3.48 | $4.12 | $3.132 | $3.38 | 4.35M |
| Sep 8, 2026 | $4.00 | $4.15 | $3.845 | $3.89 | 1.38M |
| Sep 4, 2026 | $3.53 | $4.05 | $3.515 | $3.89 | 2.23M |
| Sep 3, 2026 | $3.71 | $3.74 | $3.45 | $3.565 | 812.18K |
| Sep 2, 2026 | $3.45 | $3.77 | $3.435 | $3.75 | 731.71K |
| Sep 1, 2026 | $3.24 | $3.57 | $3.18 | $3.44 | 590.7K |
| Aug 31, 2026 | $3.20 | $3.28 | $3.0501 | $3.24 | 469.51K |
| Aug 28, 2026 | $3.32 | $3.3796 | $3.20 | $3.23 | 211.99K |
| Aug 27, 2026 | $3.31 | $3.37 | $3.23 | $3.32 | 396.78K |
| Aug 26, 2026 | $3.03 | $3.36 | $3.00 | $3.34 | 634.7K |
| Aug 25, 2026 | $2.96 | $3.09 | $2.94 | $3.06 | 422.22K |
| Aug 24, 2026 | $3.02 | $3.07 | $2.825 | $2.96 | 837.59K |
| Aug 21, 2026 | $3.15 | $3.21 | $3.02 | $3.08 | 682.28K |
| Aug 20, 2026 | $3.30 | $3.39 | $3.03 | $3.12 | 716.27K |
| Aug 19, 2026 | $3.07 | $3.50 | $3.06 | $3.37 | 1.04M |
| Aug 18, 2026 | $3.03 | $3.13 | $2.97 | $2.99 | 353.48K |
| Aug 17, 2026 | $3.03 | $3.09 | $2.83 | $3.02 | 558.94K |
| Aug 14, 2026 | $2.99 | $3.08 | $2.8616 | $3.01 | 703.83K |
| Aug 13, 2026 | $2.95 | $3.35 | $2.75 | $3.01 | 1.27M |
Latest PYXS news
The latest Smart Investors Daily articles mentioning PYXS.
Stock researchCompany · Overview
PYXS research
Overview
Company profile and research snapshot.
Company profile
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $7.50
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 10, 2026 | Wedbush | Outperform | — |
| Sep 9, 2026 | Wells Fargo | Overweight | — |
| Aug 18, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
globenewswire.com · Nov 3, 2025
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025:
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
